Skip to content

Perrigo Company PRGO Specialty Care — Net Sales

Other segment segments

Self Care
$543.3M
Infant Formula
$89.7M

Similar metrics at other companies

Balchem logo
BCPCSpecialty Products — Net Sales
$34.73M+4.4%
Amneal Pharmaceuticals, Inc. logo
AMRXSpecialty — Net revenue
$133.27M+23.1%
Perimeter Solutions logo
PRMSpecialty Products — Net Sales
$79.63M+128%
Trimas logo
TRSSpecialty Products — Net Sales
$29.11M+17.0%
Albemarle logo
ALBSpecialties — Net Sales
$358.41M+11.7%
Element Solutions logo
ESISpecialties — Net Sales
$206.5M+3.6%

Other financials

Income statement

See full
Revenue$969.2M-7.2%
Gross profit$325.5M-17.0%
Operating income-$372.3M-894%
Net income-$398.6M-6,128%
EPS (diluted)-$2.87-5,640%

Balance sheet

See full
Cash & equivalents$357.2M-12.9%
Total debt$3.8B-0.6%
Total equity$2.5B-42.7%
Total assets$8.0B-18.2%

Cash flow

See full
Operating cash flow-$113.6M-76.1%
CapEx$13.8M-45.9%
Free cash flow-$127.4M-41.6%

Valuation

See full
Market cap$1.35B-62.9%
Enterprise value$4.82B-32.0%
P/S0.3×-0.5×

Profitability

See full
Gross margin34.2%-2.2pp
Operating margin-36.9%-41.8pp
Net margin-43.5%-48.6pp
FCF margin4.2%-2.0pp

Returns & leverage

See full
Return on equity-53%-57.7pp
Debt / equity1.5×+0.6×
Current ratio2.7×+0.4×

Where this comes from

Reported directly by Perrigo Company in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Perrigo Company’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perrigo Company's specialty care — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perrigo Company's specialty care — net sales?
Perrigo Company (PRGO) reported specialty care — net sales of $207M in Q1 2026.
What does specialty care — net sales mean?
Represents the total revenue generated from the sale of products within the Specialty Care business segment. This metric reflects the market demand and commercial success of the segment's specialized pharmaceutical or healthcare offerings. It is a primary indicator of the segment's top-line growth and contribution to the overall corporate revenue stream.